Debora Fumagalli

List of Publications by Year
in descending order

51 papers	4,098 citations	218381 26 h-index	205818 48 g-index
51 all docs	51 docs citations	51 times ranked	5849 citing authors

#	Article	IF	Citations
1	Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. New England Journal of Medicine, 2021, 384, 2394-2405.	13.9	764
2	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1bâ€“2 trial. Lancet Oncology, The, 2019, 20, 371-382.	5.1	327
3	Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. Journal of Clinical Oncology, 2014, 32, 2794-2803.	0.8	298
4	Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value. Clinical Cancer Research, 2012, 18, 6531-6541.	3.2	272
5	Genomic Characterization of Primary Invasive Lobular Breast Cancer. Journal of Clinical Oncology, 2016, 34, 1872-1881.	0.8	249
6	PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2â€“Targeted Therapies in Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1334-1339.	0.8	201
7	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncology, The, 2021, 22, 476-488.	5.1	179
8	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. Journal of Clinical Oncology, 2021, 39, 1448-1457.	0.8	171
9	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, The, 2021, 22, 212-222.	5.1	169
10	Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer. Journal of the National Cancer Institute, 2013, 105, 960-967.	3.0	138
11	Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptorâ€“Positive Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4160-4167.	0.8	120
12	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. JAMA Oncology, 2017, 3, 227.	3.4	118
13	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. Journal of Clinical Oncology, 2017, 35, 1421-1429.	0.8	116
14	Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31. Journal of the National Cancer Institute, 2013, 105, 1782-1788.	3.0	94
15	The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data. Clinical Cancer Research, 2017, 23, 2702-2712.	3.2	82
16	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discovery, 2021, 11, 2796-2811.	7.7	79
17	Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. Clinical Cancer Research, 2019, 25, 3581-3588.	3.2	73
18	Molecular Profiling: Moving Away from Tumor Philately. Science Translational Medicine, 2010, 2, 47ps43.	5.8	71

#	Article	IF	Citations
19	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncology, The, 2012, 13, e240-e248.	5.1	64
20	Survival outcomes of the NeoALTTO study (BIG 1â€“06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. European Journal of Cancer, 2019, 118, 169-177.	1.3	51
21	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Research and Treatment, 2018, 168, 631-638.	1.1	49
22	Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition. Current Opinion in Oncology, 2012, 24, 623-634.	1.1	44
23	Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. Clinical Cancer Research, 2016, 22, 5238-5248.	3.2	43
24	Lucitanib for the Treatment of HR+/HER2â˜’ Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. Clinical Cancer Research, 2020, 26, 354-363.	3.2	40
25	Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591982771.	1.4	38
26	Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?. Cancer Treatment Reviews, 2014, 40, 1089-1095.	3.4	30
27	Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis. PLoS ONE, 2013, 8, e62451.	1.1	27
28	Unravelling the epigenomic dimension of breast cancers. Current Opinion in Oncology, 2011, 23, 559-565.	1.1	26
29	<scp>G</scp>enomic hotspots but few recurrent fusion genes in breast cancer. Genes Chromosomes and Cancer, 2018, 57, 331-338.	1.5	18
30	Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. Lancet Oncology, The, 2011, 12, 1162-1168.	5.1	17
31	New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors. Clinical Cancer Research, 2014, 20, 6242-6246.	3.2	15
32	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. Oncotarget, 2015, 6, 30306-30316.	0.8	14
33	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. JAMA Oncology, 2018, 4, e181564.	3.4	13
34	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. European Journal of Cancer, 2022, 166, 219-228.	1.3	12
35	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. European Journal of Cancer, 2019, 118, 1-9.	1.3	11
36	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). European Journal of Cancer, 2021, 148, 287-296.	1.3	11

#	Article	IF	Citations
37	Gene Profiling Assay and Application: The Predictive Role in Primary Therapy. Journal of the National Cancer Institute Monographs, 2011, 2011, 124-127.	0.9	9
38	Pharmacokinetic and exploratory exposureâ€“response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer Chemotherapy and Pharmacology, 2019, 83, 1147-1158.	1.1	8
39	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Clinical Cancer Research, 2021, 27, 6307-6313.	3.2	8
40	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clinical Cancer Research, 2021, 27, 5607-5618.	3.2	5
41	Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC).. Journal of Clinical Oncology, 2018, 36, 521-521.	0.8	5
42	Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays. PLoS ONE, 2018, 13, e0203346.	1.1	4
43	Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. Anti-Cancer Drugs, 2019, 30, 866-872.	0.7	4
44	Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. British Journal of Cancer, 2021, 125, 38-47.	2.9	4
45	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. Journal of the National Cancer Institute, 2022, 114, 1117-1126.	3.0	3
46	Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831. JNCI Cancer Spectrum, 2020, 4, pkaa058.	1.4	2
47	Integrate: a new model in collaborative breast cancer research. Breast, 2011, 20, S26-S27.	0.9	1
48	Research Highlights. Pharmacogenomics, 2011, 12, 9-13.	0.6	1
49	Strategies to Incorporate Translational Research Science into Clinical Trials in Breast Cancer. Current Breast Cancer Reports, 2010, 2, 208-213.	0.5	0
50	A time series evaluation of the in vivo effect of letrozole on gene expression in breast cancer. Pharmacogenomics, 2011, 12, 10.	0.6	0
51	Gene-expression changes over time in a tamoxifen-treated breast cancer xenograft model. Pharmacogenomics, 2011, 12, 11.	0.6	0